AOD-9604 (5mg Vial) Research Protocol & Reconstitution Guide
Navigation Menu
Quickstart Protocol Highlights
AOD-9604 (Advanced Obesity Drug) is a synthetic peptide fragment derived from the C-terminal end of human growth hormone (hGH). It specifically targets the lipolytic (fat-burning) properties of GH without impacting blood glucose levels or stimulating systemic growth, making it a primary subject for metabolic and adipose tissue research.
Standard Dosing & Titration Schedule
In most preclinical research models, a structured titration approach is utilized to identify the subject's metabolic responsiveness. While AOD-9604 is characterized by its high safety profile and lack of impact on IGF-1, lab consistency is maintained by starting with a baseline mcg delivery and scaling based on data requirements.
| Duration | Daily Research Dose | Draw Volume (2.5mg/mL) |
|---|---|---|
| Weeks 1 – 2 (Introductory) | 300 mcg | 12 Units (0.12 mL) |
| Weeks 3 – 8 (Standard Protocol) | 500 mcg | 20 Units (0.20 mL) |
| Weeks 9 – 12 (Intensive Study) | 1,000 mcg (1mg) | 40 Units (0.40 mL) |
Note: For optimal research results, administration is typically performed in a fasted state (e.g., first thing in the morning) to ensure the peptide's signaling pathways are not blunted by post-prandial insulin spikes.
Required Laboratory Supplies
Maintaining a strictly sterile research environment is paramount for data integrity. Based on a standard 12-week daily research cycle at 500mcg/day, the following inventory is required:
Peptide Inventory
- AOD-9604 Vials: 9 x 5mg Vials (Total 45mg).
- Based on a 500mcg/day average protocol.
Diluents & Syringes
- Bacteriostatic Water: 2 x 10mL bottles (BWFI).
- Insulin Syringes: 100 x U-100 (0.3ml or 0.5ml preferred).
Sanitization & Disposal
- Prep Pads: 200 x 70% Isopropyl Alcohol swabs.
- Sharps Container: 1 x Biohazard disposal unit.
Step-by-Step Reconstitution Guide
The physical act of reconstitution is critical. AOD-9604 is a fragile peptide fragment; improper handling can cause peptide chain fragmentation, which significantly reduces the accuracy of metabolic data.
- Sterilization: Wipe the rubber stoppers of both the AOD-9604 vial and the Bacteriostatic Water vial with a fresh alcohol swab. Allow 30 seconds to air dry.
- Pressure Equalization: Draw 2.0 mL of air into your syringe and inject it into the Bac Water vial. This makes it easier to draw the liquid out.
- Draw Diluent: Slowly draw 2.0 mL of Bacteriostatic Water into the syringe.
- Controlled Injection: Insert the needle into the AOD-9604 vial at a 45-degree angle. Drip the water slowly down the glass wall. Do not inject directly onto the lyophilized powder pellet.
- Dissolution: Gently roll the vial between your palms. Do not shake. Shaking introduces air bubbles and can cause denaturation of the peptide bonds.
- Stabilization: Allow the reconstituted vial to sit in the refrigerator (2–8°C) for at least 15 minutes before drawing your first dose.
Administration Technique & Site Rotation
AOD-9604 is administered via subcutaneous (SubQ) injection. While it acts systemically, researchers often choose abdominal adipose tissue to mimic localized lipid metabolic studies.
- Pinch Method: Gently pinch a 1-inch fold of skin at the injection site.
- Angle: Insert the needle at a 45 to 90-degree angle.
- Slow Delivery: Depress the plunger steadily. There is no need to aspirate for subcutaneous injections.
- Rotation: Rotate sites daily in a clockwise fashion around the abdomen or upper thighs to prevent localized sensitivity or scar tissue formation.
Technical Appendix: Molecular Mechanics & Lipolytic Signaling
This section provides the technical depth required for institutional research and advanced laboratory analysis of the AOD-9604 molecule.
I. Lipolysis vs. Lipogenesis: The Metabolic Pivot
AOD-9604 mimics the action of the natural GH molecule (residues 177-191). It activates the β3-adrenergic receptors, which triggers **lipolysis**—the breakdown of lipids and triglycerides into free fatty acids. Simultaneously, it inhibits **lipogenesis**, the process by which non-fatty foods are converted into body fat. This dual action is researched for its ability to reduce adipose tissue without the diabetic-like side effects associated with full-sequence GH.
II. Selective Metabolic Pathway Activation
A key research interest in AOD-9604 is its lack of interaction with the IGF-1 (Insulin-like Growth Factor 1) pathway. Because it does not trigger systemic growth or insulin resistance, it is studied as a safer alternative to traditional growth hormone for metabolic research, particularly in subjects where glucose control is a variable of concern.
III. Impact on Cartilage and Regenerative Research
Beyond adipose tissue, emerging studies have explored AOD-9604 for its potential role in cartilage repair. Research indicates that when applied to chondrocytes, the peptide may promote regeneration, leading to its inclusion in musculoskeletal and osteoarthritis research models.
IV. Stability, Storage, and Lifecycle Analysis
- Lyophilized State: Stable at room temperature for 30–60 days. Store at -20°C for long-term (2+ years) research integrity.
- Reconstituted State: Once mixed, the solution must be kept in cold storage at 2–8°C. Potency is highest for the first 21 days; after 30 days, the peptide begins a process of hydrolysis.
- Photosensitivity: UV light triggers peptide bond cleavage. Store vials in an opaque box or a dark refrigerator at all times.
V. Advanced Troubleshooting & Research FAQ
Q: My AOD-9604 is difficult to dissolve. What should I do?
A: AOD-9604 can sometimes be stubborn. Do not shake. Allow the vial to sit at room temperature for 10 minutes, then gently roll it between your palms again. If particulates remain, the pH of the diluent may be a factor.
Q: Why is a fasted state recommended for research?
A: Insulin is the body's primary anti-lipolytic hormone. If insulin levels are high (post-meal), it can neutralize the signaling pathways activated by AOD-9604, leading to skewed or diminished research data.
VI. Clinical References and Citations
- Heffernan M, et al. (2001). "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism." Endocrinology.
- Ng FM, et al. (2000). "Metabolic studies of a synthetic lipolytic fragment (AOD9604) of human growth hormone." Hormone Research.
- Heffernan M, et al. (2001). "AOD9604: A lipolytic fragment of hGH that lacks the growth-promoting and insulin-mimetic activities." Journal of Clinical Endocrinology and Metabolism.
- Stier H, et al. (2013). "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans." Journal of Endocrinology and Metabolism.
- Józwiak M, et al. (2025). "Chondrogenic potential of GH fragments: A review of AOD-9604." Pharmaceuticals (MDPI).